Post-Stroke Spasticity
11
2
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 11 trials
100.0%
+13.4% vs benchmark
27%
3 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (11)
A Pilot Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants With Post-Stroke Spasticity (The STIPS Study)
ESTIM-UL: FES for Upper Limb Recovery After Stroke
Efficacy of Focused Shock Wave Therapy Before and After Botulinum Toxin Injection in Patients With Post-Stroke Spastic Equinus/Equinovarus Foot: A Randomized Clinical Trial
Extracorporeal Shock Wave Therapy in Botulinum Toxin-Treated Patients With Post-Stroke Ankle Plantar Flexor Spasticity
Effect of NMES on Spasticity
Validity and Inter-rater Reliability for Early Recognition of Spasticity Using the Decision Tree Tool
Effect of Extracorporeal Shock Wave Therapy on Spasticity and Mobility in Stroke Patients
Dysport® Adult Lower Limb Spasticity Follow-on Study
Pain During Injection With Botulinum Toxin in Post-stroke Spasticity Treatment
Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity
Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity